Immunotherapy of Melanoma: An Update
Surgical Oncology Clinics of North America, ISSN: 1055-3207, Vol: 20, Issue: 1, Page: 145-163
2011
- 4Citations
- 23Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations4
- Citation Indexes4
- CrossRef4
- Captures23
- Readers23
- 23
Review Description
The incidence of melanoma has been increasing worldwide. A relationship between melanoma and the immune system was established years ago. Modulating the immune system in the management of different stages of melanoma has been the focus of numerous large randomized trials worldwide. This article reviews the current status of immunotherapy for melanoma, with a focus on the recent promising results from using vaccines, cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibodies, and adoptive cell therapy. © 2011 Elsevier Inc.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S1055320710000918; http://dx.doi.org/10.1016/j.soc.2010.09.004; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=78649473186&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/21111964; https://linkinghub.elsevier.com/retrieve/pii/S1055320710000918; https://dx.doi.org/10.1016/j.soc.2010.09.004
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know